Efficacy and tolerance of one-third full dose bacillus Calmette-Guérin maintenance therapy every 3 months or 6 months: Two-year results of URO-BCG-4 multicenter study

International Journal of Urology

Volumn 22, Issue 1, 2015, Pages 53-60

  Pfister, Christian ^a,j   Kerkeni, Walid ^a   Rigaud, Jerome ^b   Le Gal, Sophie ^c   Saint, Fabien ^d   Colombel, Marc ^e   Guy, Laurent ^f   Wallerand, Herve ^g   Irani, Jacques ^h   Soulie, Michel ⁱ  

^a HÔPITAL CHARLES NICOLLE   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c CAEN UNIVERSITY HOSPITAL   (France)

^d AMIENS UNIVERSITY HOSPITAL   (France)

^e HOSPICES CIVILS DE LYON   (France)

^f UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^g BORDEAUX UNIVERSITY HOSPITAL   (France)

^h POITIERS UNIVERSITY HOSPITAL   (France)

ⁱ TOULOUSE UNIVERSITY HOSPITAL   (France)

^j INSERM   (France)

more..

Author keywords

Bacillus Calmette Gu rin; Bladder cancer; Maintenance; Recurrence; Side effects

Indexed keywords

BCG VACCINE; PROSTATE SPECIFIC ANTIGEN; QUINOLONE DERIVATIVE;

ADULT; AGED; ARTICLE; BCG VACCINATION; CANCER GRADING; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INSTILLATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LEUKOCYTURIA; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE METASTASIS; NON MUSCLE INVASIVE BLADDER CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR INVASION; UNSPECIFIED SIDE EFFECT; CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIAL; DISEASE COURSE; IMMUNOLOGICAL TOLERANCE; INTRAVESICAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; PYURIA; TREATMENT OUTCOME; TUMOR RECURRENCE; URINARY BLADDER NEOPLASMS; VERY ELDERLY;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNE TOLERANCE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PYURIA; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84920928757     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.12609     Document Type: Article

References (24)

1. Sylvester RJ, Van Der Meijden APM, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol. 2002; 168: 1964-1970.
2. Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J. Urol. 2003; 169: 90-95.
3. Pfister C, Roupret M, Wallerand H etal. Recommendations Onco-Urology 2010: urothelial tumors. Prog. Urol. 2010; 20 (Suppl 4): 255-274.
4. Hall MC, Chang SS, Dalbagni G etal. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J. Urol. 2007; 178: 2314-2330.
5. Lamm DL, Blumenstein BA, Crissman JD etal. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized South West Oncology Group study. J. Urol. 2000; 163: 1124-1129.
6. Martinez-Pineiro JA, Flores N, Isorna S etal. Long-term follow-up of a randomized prospective trial comparing a standard 81mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27mg in superficial bladder cancer. BJU Int. 2002; 89: 671-680.
7. Fernandez-Gomez J, Solsona E, Unda M etal. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials. Eur. Urol. 2008; 53: 992-1001.
8. Saint F, Irani J, Patard JJ etal. Tolerability of bacille Calmette-Guerin maintenance therapy for superficial bladder cancer. Urology 2001; 57: 883-888.
9. Leibovici D, Zisman A, Chen-Levyl Z etal. Elevated specific antigen serum levels after intravesical instillation of bacillus Calmette Guerin. J. Urol. 2000; 164: 1546-1549.
10. Ratliff TL, Haaff EO, Catalona WJ. Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancer. Clin. Immunol. Immunopathol. 1986; 40: 375-379.
11. De Boer EC, De Jong WH, Steerenberg PA etal. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guerin in superficial bladder cancer. Cancer Immunol. Immunother. 1992; 34: 306-312.
12. Herr HW. Is maintenance bacillus Calmette-Guérin really necessary? Eur. Urol. 2008; 54: 971-973.
13. Pagano F, Bassi P, Piazza N etal. Improving the efficacy of BCG immunotherapy by dose reduction. Eur. Urol. 1995; 27 (Suppl 1): 19-22.
14. Ojea A, Nogueira JL, Solsona E etal. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27mg) versus very low-dose bacillus Calmette-Guerin (13.5mg) versus mitomycin C. Eur. Urol. 2007; 52: 1398-1406.
15. Lamm D. Improving patients outcomes: optimal BCG treatment regimen to prevent progression in superficial Cancer. Eur. Urol. 2006; 5: 654-659.
16. Takeda T, Kikuchi E, Yuge K etal. Discontinuance of bacillus Calmette-Guerin instillation therapy for non muscle-invasive bladder cancer has negative effect on tumor recurrence. Urology 2009; 73: 1318-1322.
17. Decobert M, LaRue H, Harel F etal. Maintenance bacillus Calmette-Guerin in high-risk nonmuscle-invasive bladder cancer: how much is enough? Cancer 2008; 113: 710-716.
18. Oddens J, Brausi M, Sylvester R etal. Final results of an EORTC-GU Cancers Group randomized study of maintenance bacillus Calmette-Guerin in intermediate and High risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur. Urol. 2013; 63: 462-472.
19. Akaza H, Hinotsu S, Aso Y etal. Bacillus Calmette-Guerin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. the Bladder Cancer BCG Study Group. Cancer 1995; 75: 552-559.
20. Sylvester RJ, van der Meijden AP, Oosterlinck W etal. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 2006; 49: 466-476.
21. Pagano F, Bassi P, Milani C, Meneghini A, Maruzzi D, Garbeglio A. A low dose bacillus Calmette Guerin regimen in superficial bladder cancer therapy: is it effective. J. Urol. 1991; 146: 32-35.
22. Van der Meijden AP, Sylvester RJ, Oosterlinck W etal. Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur. Urol. 2003; 44: 429-434.
23. Blah M, Gobet F, Dugardin F etal. Elevation of total PSA after Intravesical BCG instillations: granulomatous prostatitis or prostatic adenocarcinoma? Prog. Urol. 2008; 18: 108-113.
24. Saint F, Irani J, Salomon L etal. Urinary leukocytes as a new prognostic marker of therapeutic response and of adverse effects associated with the maintenance treatment with endovesical BCG, for the prophylaxis of superficial bladder tumors. Prog. Urol. 2001; 11: 1242-1250.